Sun Pharmaceutical, a Rs.16,000 crore pharma giant, has set to acquire Pharmalucence through its subsidiary. The company has not provided further details about acquisition.

Pharmalucence has sterile injectable capacity in the US, supported by strong R&D capabilities. The company is a New England based, employee owned manufacturer of human injectable pharmaceuticals.

Its team of greater than 100 professionals provides contract and private label formulation development and manufacturing services of non-cytotoxic human injectables in either liquid or lyophilized form. Its new 70,000 sq. ft. facility is the region's first CMO to utilize fully automated and isolated aseptic technology in support of a wide array of customer needs, from small clinical fills up to full commercial scale production for markets worldwide. This new facility, combined with its twenty plus years of experience and expertise, will provide its customers with compliance beyond currently mandated requirements.

Pharmalucence’s new facility in Billerica, Massachusetts is designed to meet world-wide compliance standards and to produce both aseptic and terminally sterilized (liquid and lyophilized) small volume parenteral products. Pharmalucence anticipates FDA approval of the new facility in 2014. Pharmalucence currently manufactures its own line of diagnostic commercial products (non-radioactive radiopharmaceuticals). In addition to these products, Pharmalucence manufactures a number of products on a contract basis for pre-clinical, clinical and commercial needs and has extensive experience with technology transfers from existing commercial sites.